Seres Therapeutics Company Profile (NASDAQ:MCRB)

About Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics logoSeres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MCRB
  • CUSIP: N/A
  • Web:
  • Market Cap: $417.27 million
  • Outstanding Shares: 40,513,000
Average Prices:
  • 50 Day Moving Avg: $13.71
  • 200 Day Moving Avg: $13.71
  • 52 Week Range: $8.85 - $17.42
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.60
  • P/E Growth: 0.03
Sales & Book Value:
  • Annual Revenue: $22.08 million
  • Price / Sales: 18.90
  • Book Value: $2.18 per share
  • Price / Book: 4.72
  • EBITDA: ($92,650,000.00)
  • Net Margins: -441.38%
  • Return on Equity: -80.21%
  • Return on Assets: -37.80%
  • Debt-to-Equity Ratio: 0.11%
  • Current Ratio: 6.86%
  • Quick Ratio: 6.86%
  • Average Volume: 276,825 shs.
  • Beta: 0.37
  • Short Ratio: 14.18

Frequently Asked Questions for Seres Therapeutics (NASDAQ:MCRB)

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.69) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.10. The company had revenue of $3 million for the quarter, compared to analysts' expectations of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business's revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.70) EPS. View Seres Therapeutics' Earnings History.

When will Seres Therapeutics make its next earnings announcement?

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Seres Therapeutics.

Where is Seres Therapeutics' stock going? Where will Seres Therapeutics' stock price be in 2017?

9 analysts have issued twelve-month target prices for Seres Therapeutics' shares. Their predictions range from $16.00 to $20.00. On average, they anticipate Seres Therapeutics' stock price to reach $18.75 in the next twelve months. View Analyst Ratings for Seres Therapeutics.

What are analysts saying about Seres Therapeutics stock?

Here are some recent quotes from research analysts about Seres Therapeutics stock:

  • 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/11/2017)
  • 2. Cowen and Company analysts commented, "Seres reported top-line results from a Phase 1b trial of SER-287 in 58 patients with." (10/2/2017)
  • 3. Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)

Who are some of Seres Therapeutics' key competitors?

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the folowing people:

  • Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer
  • Eric D. Shaff, Chief Financial Officer, Executive Vice President
  • John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing
  • David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development
  • Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary
  • Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President
  • Noubar B. Afeyan, Lead Independent Director
  • Willard H. Dere M.D., Director
  • Dennis A. Ausiello M.D., Independent Director
  • Gregory Behar, Independent Director

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

How do I buy Seres Therapeutics stock?

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of Seres Therapeutics stock can currently be purchased for approximately $10.30.

MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  281
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Seres Therapeutics (NASDAQ:MCRB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.75 (82.04% upside)
Consensus Price Target History for Seres Therapeutics (NASDAQ:MCRB)
Price Target History for Seres Therapeutics (NASDAQ:MCRB)
Analysts' Ratings History for Seres Therapeutics (NASDAQ:MCRB)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017CIBCInitiated CoverageOutperform -> Outperform$19.00N/AView Rating Details
10/12/2017Oppenheimer Holdings, Inc.Initiated CoverageOutperform$19.00N/AView Rating Details
10/12/2017Citigroup Inc.Initiated CoverageOutperform -> Positive$19.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$20.00N/AView Rating Details
10/2/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
8/30/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
8/4/2017HC WainwrightReiterated RatingBuy -> Buy$15.00 -> $19.00HighView Rating Details
8/3/2017Canaccord GenuitySet Price TargetBuy$20.00LowView Rating Details
3/20/2017FBR & CoReiterated RatingOutperform$18.00LowView Rating Details
8/11/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
8/1/2016Bank of America CorporationDowngradeBuy -> NeutralN/AView Rating Details
3/3/2016GuggenheimInitiated CoverageBuy$41.00N/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$35.00 -> $34.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Seres Therapeutics (NASDAQ:MCRB)
Earnings by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Earnings History by Quarter for Seres Therapeutics (NASDAQ MCRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.39)N/AView Earnings Details
8/3/2017Q2 2017($0.59)($0.69)$3.00 million$3.00 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.65)($0.63)$3.00 million$3.02 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.70)($0.63)$3.00 million$3.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.55)($0.46)$10.38 million$13.02 millionViewListenView Earnings Details
8/11/2016Q216($0.46)($0.70)$4.20 million$3.00 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($0.50)$1.25 million$2.71 millionViewListenView Earnings Details
11/10/2015Q315($0.32)($0.38)ViewListenView Earnings Details
8/6/2015Q215($0.30)($1.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Seres Therapeutics (NASDAQ:MCRB)
2017 EPS Consensus Estimate: ($2.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.73)($0.53)($0.63)
Q2 20172($0.61)($0.50)($0.56)
Q3 20172($0.66)($0.23)($0.45)
Q4 20172($0.74)($0.68)($0.71)
(Data provided by Zacks Investment Research)


Dividend History for Seres Therapeutics (NASDAQ:MCRB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Seres Therapeutics (NASDAQ:MCRB)
Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 74.76%
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2016John G AuninsInsiderSell9,390$10.87$102,069.30View SEC Filing  
7/28/2016Michele TrucksisInsiderSell4,156$35.18$146,208.08View SEC Filing  
7/27/2016Michele TrucksisInsiderSell38,064$35.14$1,337,568.96View SEC Filing  
7/25/2016John G AuninsInsiderSell9,390$34.18$320,950.20View SEC Filing  
7/6/2016Roger PomerantzCEOSell88,211$29.45$2,597,813.95View SEC Filing  
7/1/2016Roger PomerantzCEOSell56,789$29.81$1,692,880.09View SEC Filing  
6/30/2016Eric D ShaffCFOSell4,533$29.54$133,904.82View SEC Filing  
6/28/2016Eric D ShaffCFOSell5,001$28.28$141,428.28View SEC Filing  
6/27/2016John G AuninsEVPSell9,390$27.23$255,689.70View SEC Filing  
6/2/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
6/2/2016Roger PomerantzCEOSell74,049$32.52$2,408,073.48View SEC Filing  
6/1/2016David N CookEVPSell16,000$29.43$470,880.00View SEC Filing  
6/1/2016Roger PomerantzCEOSell70,951$30.51$2,164,715.01View SEC Filing  
5/25/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell1,000,000$27.60$27,600,000.00View SEC Filing  
5/24/2016Roger PomerantzCEOSell9,801$30.00$294,030.00View SEC Filing  
5/6/2016Roger PomerantzCEOSell8,507$24.31$206,805.17View SEC Filing  
5/5/2016Roger PomerantzCEOSell59,325$26.13$1,550,162.25View SEC Filing  
5/3/2016Roger PomerantzCEOSell67,367$28.70$1,933,432.90View SEC Filing  
4/25/2016John G AuninsEVPSell18,640$31.94$595,361.60View SEC Filing  
4/7/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
4/7/2016Roger PomerantzCEOSell9,212$30.00$276,360.00View SEC Filing  
4/4/2016David N CookEVPSell61,000$26.16$1,595,760.00View SEC Filing  
4/4/2016Eric D ShaffCFOSell6,568$28.85$189,486.80View SEC Filing  
4/4/2016Roger PomerantzCEOSell135,788$27.20$3,693,433.60View SEC Filing  
3/31/2016Eric D ShaffCFOSell7,663$26.30$201,536.90View SEC Filing  
3/28/2016Eric D ShaffCFOSell5,473$24.07$131,735.11View SEC Filing  
3/28/2016John G AuninsEVPSell9,390$23.89$224,327.10View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Seres Therapeutics (NASDAQ:MCRB)
Latest Headlines for Seres Therapeutics (NASDAQ:MCRB)
DateHeadline logoETFs with exposure to Seres Therapeutics, Inc. : October 17, 2017 - October 18 at 6:52 AM logo$18.01 Million in Sales Expected for Seres Therapeutics, Inc. (MCRB) This Quarter - October 18 at 1:48 AM logoBenzinga's Top Upgrades, Downgrades For October 13, 2017 - Benzinga - October 14 at 2:51 AM logoSeres Therapeutics, Inc. (MCRB) Research Coverage Started at CIBC - October 13 at 10:22 AM logoSeres Therapeutics, Inc. (MCRB) Coverage Initiated by Analysts at Oppenheimer Holdings, Inc. - October 12 at 6:26 PM logoSeres Therapeutics, Inc. (MCRB) Earns Positive Rating from Analysts at Citigroup Inc. - October 12 at 5:18 PM logoSeaport Global Securities Begins Coverage on Seres Therapeutics, Inc. (MCRB) - October 7 at 2:58 PM logoSeres Therapeutics, Inc. (MCRB) Given Average Rating of "Buy" by Brokerages - October 7 at 4:52 AM logoSeres Therapeutics Inc. (MCRB) Tumbled To A 2-Month Low On Study Results - October 3 at 10:23 AM logoSeres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : October 3, 2017 - October 3 at 10:23 AM logoHow Should You Think About Seres Therapeutics Inc’s (MCRB) Risks? - October 2 at 10:20 PM logoSeres Therapeutics, Inc. (MCRB) Stock Rating Reaffirmed by Cowen and Company - October 2 at 9:32 PM logoSeres Therapeutics (MCRB) Says It's 'Extremely Pleased' with ... - - October 2 at 5:17 PM logoRigel Rises on Update on FDA Review of Bleeding Disorder Treatment - October 2 at 11:59 AM logoSeres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis - October 2 at 11:59 AM logoSeres Therapeutics stock drops 19% on clinical trial results - October 2 at 11:59 AM logoCORRECTING and REPLACING Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis - October 2 at 11:59 AM logo Analysts Expect Seres Therapeutics, Inc. (MCRB) Will Announce Quarterly Sales of $23.01 Million - September 30 at 9:50 AM logoSeres Therapeutics Is Hiding A Volatile Catalyst - Seeking Alpha - September 24 at 1:12 AM logoETFs with exposure to Seres Therapeutics, Inc. : September 22, 2017 - September 23 at 8:05 AM logoSeres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 - September 21 at 6:00 PM logoSeres Therapeutics, Inc. (MCRB) Receives Average Recommendation of "Buy" from Brokerages - September 12 at 4:40 AM logo Analysts Anticipate Seres Therapeutics, Inc. (MCRB) Will Post Quarterly Sales of $23.01 Million - September 11 at 10:50 AM logo-$0.24 EPS Expected for Seres Therapeutics, Inc. (MCRB) This Quarter - September 9 at 11:50 AM logoSeres Therapeutics to Present at the Baird 2017 Global Healthcare Conference - September 1 at 3:52 AM logoSeres Therapeutics, Inc. (MCRB) Earns Buy Rating from Cantor Fitzgerald - August 31 at 7:34 PM logoSeres Therapeutics (MCRB) & Ophthotech Corporation (OPHT) Head to Head Comparison - August 30 at 12:22 AM logoSeres Therapeutics, Inc. (MCRB) Receives Consensus Rating of "Buy" from Brokerages - August 18 at 4:40 AM logoFY2017 Earnings Forecast for Seres Therapeutics, Inc. (NASDAQ:MCRB) Issued By Cantor Fitzgerald - August 10 at 10:42 AM logoLeerink Swann Research Analysts Increase Earnings Estimates for Seres Therapeutics, Inc. (NASDAQ:MCRB) - August 7 at 7:40 AM logoSeres Therapeutics, Inc. (NASDAQ:MCRB) Expected to Post Quarterly Sales of $3.00 Million - August 5 at 7:14 AM logoHC Wainwright Increases Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target to $19.00 - August 4 at 10:36 AM logoSeres Therapeutics Reports Second Quarter 2017 Financial Results ... - Business Wire (press release) - August 4 at 1:27 AM logoInvestor Network: Seres Therapeutics Inc to Host Earnings Call - August 4 at 1:27 AM logoSeres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress - August 4 at 1:27 AM logoSeres Therapeutics reports 2Q loss - August 4 at 1:27 AM logoEdited Transcript of MCRB earnings conference call or presentation 3-Aug-17 12:00pm GMT - August 4 at 1:27 AM logoSeres Therapeutics, Inc. (MCRB) Issues Quarterly Earnings Results, Misses Estimates By $0.05 EPS - August 3 at 8:52 PM logoSeres Therapeutics, Inc. (NASDAQ:MCRB) PT Set at $20.00 by Canaccord Genuity - August 3 at 7:20 PM logo Brokerages Expect Seres Therapeutics, Inc. (NASDAQ:MCRB) Will Announce Earnings of -$0.59 Per Share - August 3 at 2:20 PM logoSeres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference - August 3 at 4:44 AM logoSeres Therapeutics to Host Second Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2017 - July 28 at 3:38 AM logoSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Rating of "Buy" from Brokerages - July 24 at 10:54 AM logoSeres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2% - July 22 at 6:22 AM logo Brokerages Anticipate Seres Therapeutics, Inc. (MCRB) Will Post Earnings of -$0.57 Per Share - July 12 at 8:44 AM logoBRIEF-Seres Therapeutics says size of board increased from 7 to 8 - July 11 at 1:22 AM logoSeres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer - July 11 at 1:22 AM logoSeres Therapeutics: This Time, Success? - Seeking Alpha - June 20 at 3:31 AM logoXLRN's DART Misses Mark, RGLS Makes Cuts In Pipeline, FDA ... - Nasdaq - June 13 at 8:04 AM logoSeres Therapeutics (MCRB) Commences SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection - - June 13 at 8:04 AM



Seres Therapeutics (MCRB) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.